Novabay Pharma appoints Mark Sieczkarek president and CEO
Mr. Sieczkarek has been a NovaBay Director since January 2014, was named Chairman in April 2015 and has served as interim President and CEO since November 2015. He has been instrumental in the development and implementation of the go-to-market strategy for Avenova.
Mr. Sieczkarek previously was CEO of Solta Medical, Inc. (acquired by Valeant Pharmaceuticals) and of Conceptus, Inc. (acquired by Bayer HealthCare), where he led the launch of the medical device Essure.
Prior to that, he was Senior Vice President and President of The Americas and Europe for the leading ophthalmic company Bausch & Lomb (acquired by Valeant Pharmaceuticals), where he was responsible for overseeing multinational commercial launches of several leading products. ■
LATEST MOVES FROM California
- NuVasive appoints Rajesh J. Asarpota as CFO
- Sanmina appoints David Anderson as CFO
- RPX Corporation appoints Marty Roberts to board
- Pfenex appoints Evert Schimmelpennink as CEO
- Aqua Metals appoints Mark Weinswig as CFO
More inside POST
Rio Tinto H1 profit soars on prices Earnings